Investigation of effect of Oral Nanomicelle Curcumin in Patients with Non-atopic Bronchial Asthma

Investigation of effect of oral nanomicell curcumin on Improving of FEV1 and Quality of Life in Patients with Non-atopic Bronchial Asthma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161226031584N2

Enrollment

Registered

2019-06-17

Start date

2017-08-23

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Chronic lower respiratory diseases

Interventions

Intervention 1: Interventional group:Oral curcumin 40 mg three times a day (Sinacurcumin nanomicelle, Minoo Pharmacy Company, Tehran, Iran) as an Add-on therapy in Patients of Bronchial Asthma that th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: non atoic asthma informed consent

Exclusion criteria

Exclusion criteria: smoker COPD pregnancy/lactation heart ,liver,kidney disorder and gallbladder disease acute exacerbation within one month ago

Design outcomes

Primary

Measure	Time frame
FEV1,ACT ,AQLQ. Timepoint: Measuring the FEV1-ACT, AQLQ questionnaire every two weeks to two months. Method of measurement: questionnaire ,spirometry,physical exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahrzad Mohamadzadeh Lari

Mashhad University of Medical Sciences

larish@mums.ac.ir+98 51 3859 4083

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026